Latest Filings

Issuer Activity

Insider Overview :: Acasti Pharma Inc. (V:APO) [?]
Business Focus: Pharmaceuticals Share on StockTwits
Log in or sign up for a free account to add this stock to your watch list.

Holdings trends & enhanced charts available in PDF report. Click here for details »
Latest 10 SEDI filings (by transaction date) for APO within the last 6 months [?]
Amended Filing
As of 11:59pm ET August 26th, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Aug 26/14 Aug 25/14 Lemieux, Pierre Direct Ownership Common Shares (Actions de catégorie A) 10 - Disposition in the public market -12,500 $1.03
Aug 8/14 Aug 7/14 Turcotte, Mario Direct Ownership Options 50 - Grant of options 50,000 $1.15
Aug 6/14 Aug 5/14 Wenker, Jerald Joseph Direct Ownership Common Shares (Actions de catégorie A) 10 - Acquisition in the public market 2,500 $0.936
USD
Jul 21/14 Jul 21/14 Lauzon, Claudie Direct Ownership Common Shares (Actions de catégorie A) 10 - Disposition in the public market -3,750 $1.00
Jul 24/14 Jul 17/14 Huart, Benoît Direct Ownership Common Shares (Actions de catégorie A) 00 - Opening Balance-Initial SEDI Report 8,750  
Jul 21/14 Jul 17/14 Le Bel, Dominique Direct Ownership Options 00 - Opening Balance-Initial SEDI Report 50,000  
Jul 21/14 Jul 17/14 Le Bel, Dominique Direct Ownership Restricted Share Units 00 - Opening Balance-Initial SEDI Report 12,500  
Jul 21/14 Jul 17/14 Le Bel, Dominique Direct Ownership Common Shares (Actions de catégorie A) 00 - Opening Balance-Initial SEDI Report 12,500  
Jul 21/14 Jul 17/14 Bélanger, Jean-Daniel Direct Ownership Common Shares (Actions de catégorie A) 00 - Opening Balance-Initial SEDI Report    
Jul 21/14 Jul 17/14 Bélanger, Jean-Daniel Direct Ownership Options 00 - Opening Balance-Initial SEDI Report 25,000  
Sign up for an account or login above to see all SEDI filings within the past 6 months.
Latest 10 SEDI filings (by filing date) for APO within the last 6 months [?]
Amended Filing
As of 11:59pm ET August 26th, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Aug 26/14 Aug 25/14 Lemieux, Pierre Direct Ownership Common Shares (Actions de catégorie A) 10 - Disposition in the public market -12,500 $1.03
Aug 8/14 Aug 7/14 Turcotte, Mario Direct Ownership Options 50 - Grant of options 50,000 $1.15
Aug 6/14 Aug 5/14 Wenker, Jerald Joseph Direct Ownership Common Shares (Actions de catégorie A) 10 - Acquisition in the public market 2,500 $0.936
USD
Jul 24/14 Jul 17/14 Huart, Benoît Direct Ownership Common Shares (Actions de catégorie A) 00 - Opening Balance-Initial SEDI Report 8,750  
Jul 23/14 Jul 14/14 Turcotte, Mario Direct Ownership Options 00 - Opening Balance-Initial SEDI Report    
Jul 23/14 Jul 14/14 Turcotte, Mario Direct Ownership Common Shares (Actions de catégorie A) 00 - Opening Balance-Initial SEDI Report    
Jul 21/14 Jul 17/14 Le Bel, Dominique Direct Ownership Options 00 - Opening Balance-Initial SEDI Report 50,000  
Jul 21/14 Jul 17/14 Le Bel, Dominique Direct Ownership Restricted Share Units 00 - Opening Balance-Initial SEDI Report 12,500  
Jul 21/14 Jul 17/14 Le Bel, Dominique Direct Ownership Common Shares (Actions de catégorie A) 00 - Opening Balance-Initial SEDI Report 12,500  
Jul 21/14 Jul 21/14 Lauzon, Claudie Direct Ownership Common Shares (Actions de catégorie A) 10 - Disposition in the public market -3,750 $1.00
Sign up for an account or login above to see all SEDI filings within the past 6 months.
Sign up for an account or login above to see the past 6 months of SEDI filings sorted by insider.
No Markers (TSX Insider Summaries) for APO on August 26, 2014 [?]
To view marker data for the past week, sign up for an account or log in above.
To view more history, sign up for an account at inkresearch.com
Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEDAR
Key People
Jerald J. Wenker
Chairman of the Board
Andre Godin
Interim President and Chief Executive Officer
Pierre Lemieux
Chief Operating Officer
Harlan W. Waksal
Executive Vice President - Business and Scientific Affairs
Tina Sampalis
Chief Global Strategy Officer
Henri Harland
Secretary, Director
Company Contact
Address: Suite 100, 545 Promenade du Centropolis
LAVAL QC H7T 0A3
Tel: N/A
Website: www.acastipharma.com
IR: See website
Business Overview
Acasti Pharma Inc. (Acasti) is engaged in developing a product portfolio of long-chain omega-3 phospholipids. Acasti is a majority owned subsidiary of Neptune Technologies and Bioressources Inc. (Neptune). The Company has one operating segment: the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. The Company's product portfolio includes concentrated phospholipids which functionalize eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Acasti is the producer of anti-dyslipidemic prescription drugs (CaPre), medical foods (Onemia) and over-the-counter (OTC) products (Vectos). During the fiscal year ended February 28, 2011 (fiscal 2011), the Company has completed the development and launched medical food, Onemia.
Financial Overview
For the three months ended 31 May 2014, Acasti Pharma Inc revenues increased from C$6K to C$56K. Net income totaled C$1.4M vs. loss of C$2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -C$0.03 to C$0.01.
Reporting Currency: Canadian Dollars
Enterprise value: $85.75M as of May 31, 2014
Annual revenue (TTM): $0.55M as of May 31, 2014
EBITDA (TTM): -$9.60M as of May 31, 2014
Net annual income (TTM): -$8.29M as of May 31, 2014
Free cash flow (TTM): -$6.50M as of May 31, 2014
Net Debt Last Fiscal Year: N/A
Shares outstanding: 106,260,178 as of Jun 23, 2014
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization
Competitors with Recent Insider Filings
Valeant Pharmaceuticals (T:VRX)
Concordia Healthcare (T:CXR)
Cipher Pharmaceuticals (T:DND)
 
Acasti Pharma Inc. Insider Report Only $20.00